The Importance of Appropriate Supplier Oversight
PharmaTech
NOVEMBER 2, 2024
The product license holder must have a supplier oversight system in place, says Siegfried Schmitt, PhD, vice president, Technical, Parexel.
PharmaTech
NOVEMBER 2, 2024
The product license holder must have a supplier oversight system in place, says Siegfried Schmitt, PhD, vice president, Technical, Parexel.
Pharmacy Times
NOVEMBER 2, 2024
ASCO is prioritizing the expansion of pharmacist involvement in its organization by recognizing pharmacists' contributions to safety standards, quality improvement initiatives, and certification programs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
NOVEMBER 2, 2024
First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
Pharmacy Times
NOVEMBER 2, 2024
In children aged 12, 18, and 24 months, there was no association between maternal COVID-19 exposure and abnormal scores on a neurodevelopment screening.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Welltopia Pharmacy
NOVEMBER 2, 2024
Glutaryl Plus supplement enhances cellular health, detoxifies, and boosts immunity with powerful antioxidant support. Glutaryl + by Auro Wellness has become a popular choice for enhancing cellular health and antioxidant support in the pursuit of optimal health.
Pharmacy Times
NOVEMBER 2, 2024
If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).
Let's personalize your content